| P50 | author | Alexandru Almasan | Q55313957 |
| P2093 | author name string | Huayuan Zhu | |
| P2860 | cites work | Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function | Q24293924 |
| | Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins | Q24302494 |
| | Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members | Q24337108 |
| | miR-15 and miR-16 induce apoptosis by targeting BCL2 | Q24536069 |
| | Targeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisib | Q27025812 |
| | ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets | Q27683708 |
| | Structure-guided design of a selective BCL-X(L) inhibitor | Q27684453 |
| | Second-generation inhibitors of Bruton tyrosine kinase | Q28076118 |
| | Therapeutic potential of new B cell-targeted agents in the treatment of elderly and unfit patients with chronic lymphocytic leukemia | Q28087378 |
| | Idelalisib and rituximab in relapsed chronic lymphocytic leukemia | Q28306347 |
| | ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells | Q28307506 |
| | The BCL-2 protein family: opposing activities that mediate cell death | Q29547380 |
| | An inhibitor of Bcl-2 family proteins induces regression of solid tumours | Q29547595 |
| | The landscape of somatic copy-number alteration across human cancers | Q29547648 |
| | ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor | Q29616727 |
| | The Bcl-2 protein family: arbiters of cell survival | Q29618158 |
| | Bcl-2high mantle cell lymphoma cells are sensitized to acadesine with ABT-199. | Q30395557 |
| | Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity | Q33392920 |
| | Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease | Q33398808 |
| | MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies | Q33419789 |
| | Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. | Q33421292 |
| | Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study | Q33432228 |
| | Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study | Q33438428 |
| | Cell death | Q34019760 |
| | Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia | Q34504188 |
| | Multiple BH3 mimetics antagonize antiapoptotic MCL1 protein by inducing the endoplasmic reticulum stress response and up-regulating BH3-only protein NOXA. | Q35107469 |
| | Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes. | Q35183982 |
| | An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737. | Q35266213 |
| | Acidosis Sensing Receptor GPR65 Correlates with Anti-Apoptotic Bcl-2 Family Member Expression in CLL Cells: Potential Implications for the CLL Microenvironment | Q35606359 |
| | Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1 | Q35920657 |
| | Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia | Q35958056 |
| | Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia | Q36000944 |
| | Initial treatment of CLL: integrating biology and functional status | Q36219647 |
| | Cyclin E/Cdk2-dependent phosphorylation of Mcl-1 determines its stability and cellular sensitivity to BH3 mimetics | Q36231912 |
| | miR-377-dependent BCL-xL regulation drives chemotherapeutic resistance in B-cell lymphoid malignancies. | Q36247617 |
| | BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics. | Q36468244 |
| | Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia | Q36490049 |
| | Bcl-2-family proteins and hematologic malignancies: history and future prospects | Q36508817 |
| | MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma | Q36546300 |
| | Defining specificity and on-target activity of BH3-mimetics using engineered B-ALL cell lines | Q36998291 |
| | The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. | Q37035832 |
| | Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas | Q37058203 |
| | High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells | Q37209768 |
| | ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development | Q38640917 |
| | Using the pathology report in initial treatment decisions for diffuse large B-cell lymphoma: time for a precision medicine approach | Q38659597 |
| | The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models | Q38736457 |
| | Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma | Q38742685 |
| | BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199. | Q38776895 |
| | Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models | Q38789183 |
| | Cyclin-dependent kinase inhibitors for the treatment of chronic lymphocytic leukemia | Q38797086 |
| | Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax | Q38808802 |
| | Bcl-2 phosphorylation confers resistance on chronic lymphocytic leukaemia cells to the BH3 mimetics ABT-737, ABT-263 and ABT-199 by impeding direct binding | Q38825797 |
| | The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in chronic lymphocytic leukaemia cells through downregulation of Mcl-1. | Q38826234 |
| | Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma. | Q38827910 |
| | Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma | Q38896657 |
| | Structure-guided design of a series of MCL-1 inhibitors with high affinity and selectivity | Q38910043 |
| | BCL2 Inhibitors as Anticancer Drugs: A Plethora of Misleading BH3 Mimetics | Q38930539 |
| | ABT-199, a BH3 mimetic that specifically targets Bcl-2, enhances the antitumor activity of chemotherapy, bortezomib and JQ1 in "double hit" lymphoma cells | Q38942453 |
| | Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma. | Q38999783 |
| | CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors | Q39139055 |
| | Mcl-1 Phosphorylation defines ABT-737 resistance that can be overcome by increased NOXA expression in leukemic B cells | Q39360515 |
| | ABT-737 induces apoptosis in mantle cell lymphoma cells with a Bcl-2high/Mcl-1low profile and synergizes with other antineoplastic agents | Q39494067 |
| | bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia | Q41527925 |
| | Acquired resistance to venetoclax (ABT-199) in t(14;18) positive lymphoma cells | Q42317487 |
| | Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors. | Q42399858 |
| | The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma | Q42748426 |
| | The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia | Q43090573 |
| | Metabolism and Disposition of a Novel B-Cell Lymphoma-2 Inhibitor Venetoclax in Humans and Characterization of Its Unusual Metabolites. | Q46443260 |
| | Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1. | Q48139370 |
| | Clinical Predictors of Venetoclax Pharmacokinetics in Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma Patients: a Pooled Population Pharmacokinetic Analysis. | Q51283983 |
| | Hypoxia-induced p38 MAPK activation reduces Mcl-1 expression and facilitates sensitivity towards BH3 mimetics in chronic lymphocytic leukemia. | Q51685717 |
| | Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia. | Q53093058 |
| | Bcl-2 family proteins are essential for platelet survival. | Q53581386 |
| | Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways. | Q55070853 |
| | Involvement of the bcl-2 gene in human follicular lymphoma | Q69870224 |
| | The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells | Q86516013 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial | Q6936496 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | amides | Q188777 |
| | antineoplastic | Q2853144 |
| | sulfonamide | Q3208529 |
| | B-cell lymphoma | Q4833719 |
| P1104 | number of pages | 10 | |
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 685-694 | |
| P577 | publication date | 2017-03-09 | |
| P1433 | published in | Drug Design, Development and Therapy | Q2566724 |
| P1476 | title | Development of venetoclax for therapy of lymphoid malignancies | |
| P478 | volume | 11 | |